Hemab is a Biotech company based in Cambridge. It has raised $537M in total funding. Latest round: IPO.
Hemab funding overview
Hemab is a Biotech company based in Cambridge. Hemab has raised $537M in total disclosed funding. That places its disclosed total in the $250M–$1B range. Its most recent disclosed round is an IPO announced in May 2026. The round record for Hemab runs through 2026; nothing later has been disclosed. Investors on record include Novo Holdings, HealthCap, RA Capital Management, Access Biotechnology, Novo Seeds. 5 distinct backers are named across the disclosed rounds.
Hemab at a glance
Total raised
$537M
Latest round
IPO
Latest round date
May 2026
Industry
Biotech
Headquarters
Cambridge
Notable investors
Novo Holdings, HealthCap, RA Capital Management, Access Biotechnology, Novo Seeds
Frequently asked about Hemab funding
How much has Hemab raised?
Hemab has raised $537M in total disclosed funding across the rounds on record.
Who has invested in Hemab?
Novo Holdings, HealthCap, RA Capital Management, Access Biotechnology, Novo Seeds are named among the investors backing Hemab.
What was the latest Hemab funding round?
The most recent disclosed round is an IPO, announced in May 2026.
Where is Hemab based?
Hemab is based in Cambridge.
What sector does Hemab operate in?
Hemab is tracked under Biotech from Cambridge, with $537M in disclosed funding.
When did Hemab last raise?
The last disclosed Hemab round closed in May 2026 at IPO.
Totals shown for Hemab aggregate every disclosed round on file. To see how that compares, browse the Biotech companies in Cambridge and the investors behind them below.
